Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
ImmunoCellular Therapeutics (IMUC)
OTHER OTC:IMUC
Holding IMUC?
Track your performance easily
IMUC Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.07 - $0.40
Previous Close$0.2
Volume1.21K
Average Volume (3M)1.95K
Market Cap
$22.65M
Enterprise Value$19.80M
Total Cash (Recent Filing)$2.85M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta-0.37
Next Earnings
Aug 13, 2018EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding113,270,751
10 Day Avg. Volume2,614
30 Day Avg. Volume1,949
Standard Deviation0.32
R-Squared0.00303
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)0.00
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-3.51
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
IMUC FAQ
What was ImmunoCellular Therapeutics’s price range in the past 12 months?
ImmunoCellular Therapeutics lowest stock price was $0.07 and its highest was $0.40 in the past 12 months.
What is ImmunoCellular Therapeutics’s market cap?
Currently, no data Available
When is ImmunoCellular Therapeutics’s upcoming earnings report date?
ImmunoCellular Therapeutics’s upcoming earnings report date is Aug 13, 2018 which is 2293 days ago.
How were ImmunoCellular Therapeutics’s earnings last quarter?
Currently, no data Available
Is ImmunoCellular Therapeutics overvalued?
According to Wall Street analysts ImmunoCellular Therapeutics’s price is currently Overvalued.
Does ImmunoCellular Therapeutics pay dividends?
ImmunoCellular Therapeutics does not currently pay dividends.
What is ImmunoCellular Therapeutics’s EPS estimate?
ImmunoCellular Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does ImmunoCellular Therapeutics have?
ImmunoCellular Therapeutics has 113,270,750 shares outstanding.
What happened to ImmunoCellular Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of ImmunoCellular Therapeutics?
Currently, no hedge funds are holding shares in IMUC
---
ImmunoCellular Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Company Description
ImmunoCellular Therapeutics
ImmunoCellular Therapeutics, Ltd. is a clinical-stage company, which engages in the development of immune-based therapies for the treatment of cancers. The company's lead product candidate, ICT-107, is a dendritic cell-based immunotherapy targeting multiple tumor-associated antigens on glioblastoma stem cells. Its pipeline also includes ICT-121, a patient-specific, dendritic cell-based immunotherapy targeting the CD133 antigen on stem cells in recurrent glioblastoma; ICT-140, a patient-specific, dendritic cell-based immunotherapy targeting antigens on ovarian cancer stem cells; and the Stem-to-T-cell research program which engineers the patient's hematopoietic stem cells to generate antigen-specific cancer-killing T cells. The company was founded on January 30, 2006 and is headquartered in Calabasas, CA.
---
Technical Analysis
Northwest Biotherapeutics
―
Advaxis
―
Brainstorm Cell Therapeutics
―
Cyclacel Pharmaceuticals
―
---